AmeriHealth Caritas Foundation Awards $1.9 Million in Grants to Advance the Well-Being of Children and Families
Newtown Square, Pennsylvania--(Newsfile Corp. - November 18, 2025) - The AmeriHealth Caritas Foundation awarded grants totaling $1.9 million to nonprofits delivering housing stability, health care access, and parenting support to reduce the impact of adverse childhood experiences. The funding supports 16 organizations across eight states and the District of Columbia with initiatives aiming to strengthen families, increase ch
Healthcare and Hospitals, Health
2025-11-18 11:30 AM EST | AmeriHealth Caritas Foundation
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference from December 11-14, 2025 in Key West, Florida. The company will highlight its world-leading angiogenic cell therapy, ACP-01, which regenerates circulation, heals ulcers, alleviates pain, and improves quality of life for patients with advanced wound care needs including Peri
Biotechnology, Pharmaceuticals, Health
2025-11-18 11:30 AM EST | Hemostemix Inc.
AAMI Updates Medical Device Design Standard for First Time Since 2009
Arlington, Virginia--(Newsfile Corp. - November 18, 2025) - How medical professionals interact with medical devices is an increasingly vital consideration for the manufacturers who design those medical devices. The Association for the Advancement of Medical Instrumentation (AAMI) has updated its primary human factors engineering guidance for the medical device industry for the first time in over fifteen years.
2025-11-18 8:54 AM EST | Association for the Advancement of Medical Instrumentation
DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025 and October 24, 2025, the Company is pleased to announce that it has closed its non-brokered private placement of units ("Units") with each Unit consisting of one common share in the capital of the Company (each a "Share") an
2025-11-18 8:30 AM EST | DiagnosTear Technologies Inc.
Aleen Inc. Identifies Core Insights from Concept Testing Phase
Toronto, Ontario--(Newsfile Corp. - November 18, 2025) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announced the completion of its initial concept testing for the upcoming Smart Analytics feature. The research provided valuable insight into how users interact with wellness tools and what they expect from digital self-awareness platforms. The findings revealed three consistent user priorities: Clear visualization of personal wellness patterns; Strong privac
2025-11-18 8:08 AM EST | Aleen Inc.
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 3 months, commencing on November 18, 2025
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-18 7:00 AM EST | TempraMed Technologies Ltd
FendX and Aquaox Sign MOU to Pursue Innovation in Sustainable Pathogen Elimination
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has signed a Memorandum of Understanding ("MOU") dated November 17, 2025 with Aquaox LLC ("Aquaox"), a U.S. based manufactu
Technology, Healthcare and Hospitals, Health
2025-11-18 6:30 AM EST | FendX Technologies Inc.
Predictmedix AI Announces Closing of $460,150 First Tranche
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce the successful closing of the first tranche of its non-brokered private placement. The Company issued 9,203,000 units ("Units") at an issue price of $0.05 per Unit, raising gross proceeds of $460,150. Notably, $60,000 of the tranche was subscribed by insid
2025-11-17 5:02 PM EST | Predictmedix AI Inc.
Mobile-health Network Solutions Co-CEO Teoh Pui Pui Increases Equity Stake Through Open Market Purchase
Singapore, Singapore--(Newsfile Corp. - November 17, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced that its co-founder, co-CEO, COO, and Chairwoman of the Board, Dr. Teoh Pui Pui, has acquired additional shares of the company's Class A Ordinary Shares through an independent open market transaction. According to a Schedule 13D filed today with the U.S. Securities and Exchange Commis
2025-11-17 4:30 PM EST | Mobile-health Network Solutions
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:45 AM EST | Phio Pharmaceuticals Corp.
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan facility. The term loan facility benefits from an additional US$10.0 million delayed draw feature, intended to finance future licensing and acquisitio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:30 AM EST | Medexus Pharmaceuticals Inc.
ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC Markets
Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Markets to update from 6719 (Holding Companies, N.E.C.) to 2836 (Biological Products, Except Diagnostic), accurately reflecting its core business of manufacturin
Healthcare and Hospitals, Health
2025-11-17 8:00 AM EST | Adia Nutrition Inc.
Scryb Highlights New U.S. Institutional Fund Investment in Cybeats; Strengthens Long-Term Outlook
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to highlight the closing of an investment by U.S.-based IFCM MicroCap Fund LP, managed by Intelligent Fanatics Capital Management, into Cybeats Technologies Corp. ("Cybeats"). The investment fund was the sole participant in this $1.44 million private placement.1 Scryb maintains its position as the largest institutional shareholder of Cybeats
Biotechnology, Healthcare and Hospitals, Health
2025-11-17 7:00 AM EST | Scryb Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-14 4:19 PM EST | Elite Pharmaceuticals, Inc.
RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation License
Toronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potenti
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-11-14 8:30 AM EST | Akanda Corp
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to
Healthcare and Hospitals, Health
2025-11-14 1:10 AM EST | Cosmo Pharmaceuticals N.V.
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Safety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762 Warrant Inducement Fi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-13 4:15 PM EST | Phio Pharmaceuticals Corp.
Akanda Researching Security Requirements for Full Cultivation License
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potenti
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-11-13 4:05 PM EST | Akanda Corp
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a
Biotechnology, Pharmaceuticals, Health
2025-11-13 4:05 PM EST | BioHarvest Sciences Inc.
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to the University of Florida (UF, Gainesville) vascular team. The session, titled "Angiogenic Cell Precursors (ACP-01): Regenerating Microcirculation in CLI, Cardiomyopathy and Angina," was delivered by Fraser Henderson Sr., MD (neurosurgeon) with opening remarks and poli
Biotechnology, Pharmaceuticals, Health
2025-11-13 10:57 AM EST | Hemostemix Inc.